These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 24954503)

  • 1. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Spaargaren M; de Rooij MF; Kater AP; Eldering E
    Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Flinn IW
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
    [No Abstract]   [Full Text] [Related]  

  • 7. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
    Dias AL; Jain D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Kaur V; Swami A
    Ann Hematol; 2017 Jul; 96(7):1175-1184. PubMed ID: 28342031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
    Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
    Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
    [No Abstract]   [Full Text] [Related]  

  • 13. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
    Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
    N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib for the treatment of chronic lymphocytic leukemia.
    Deodato M; Frustaci AM; Zamprogna G; Cairoli R; Montillo M; Tedeschi A
    Expert Rev Hematol; 2019 May; 12(5):273-284. PubMed ID: 30916599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.